Radiology

Permanent URI for this collection

https://hdl.handle.net/20.500.14709/68

Browse

Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ
(Radiological Society of North America, 2025-11-18) Hou, Rui; Grimm, Lars; Marks, Jeffrey; King, Lorraine; Lynch, Thomas; Rogers, Keith; LYBURN, IAIN; Stone, Nick; Wallis, Matthew; Mann, Ritse; Lips, Esther; Alaeikhanehshir, Sena; van Leewen, Merle; Teuwen, Jonas; Wesseling, Jelle; Lo, Joseph; Hwang, Shelley; Lyburn, Iain; Medical and Dental
Background Patients diagnosed with ductal carcinoma in situ (DCIS) may also have undetected invasive breast cancer. Radiomic features of calcifications at mammography can predict occult invasive disease among women diagnosed with DCIS at core-needle biopsy, which could affect treatment recommendations. However, the generalizability of these radiomic models must be tested before they are adopted in clinical practice. Purpose To evaluate the generalizability of radiomic models based on mammography features to predict occult invasive cancer among women diagnosed with DCIS at core-needle biopsy from three national datasets. Materials and Methods In this retrospective, cross-national study, digital mammograms from women diagnosed with DCIS at breast core-needle biopsy were collected in the United States, United Kingdom, and the Netherlands between January 1, 2000, and December 31, 2021. Only asymptomatic women who had calcifications but did not have associated masses, architectural distortions, or asymmetries were included. Radiomic models were developed using cross-validated logistic regression on each national dataset, then round-robin tested on the other datasets. Differences across the three datasets in terms of the upstaging rate, age, lesion size, and estrogen and progesterone receptor levels were assessed using Kruskal-Wallis or χ2 test. Results The study included 1498 women (age range, 31–89 years; mean age, 59 years ± 9 [SD]), as follows: 696 women from the United States, 618 women from the United Kingdom, and 184 women from the Netherlands, with upstaging rates of 16.1%, 16.7%, and 14.1%, respectively. Internal cross-validation areas under the receiver operating characteristic curve (AUCs) were 0.675 (95% CI: 0.671, 0.679), 0.603 (95% CI: 0.567, 0.722), and 0.701 (95% CI: 0.697, 0.706) for the U.S., UK, and Netherlands datasets, respectively. The model that was trained on the U.S. dataset yielded cross-national validation AUCs of 0.604 (95% CI: 0.560, 0.648) and 0.682 (95% CI: 0.607, 0.757) for the UK and Netherlands datasets. Conclusion Radiomic machine learning models were shown to have the potential to predict occult invasive cancer in women with DCIS across diverse settings.
Radiotherapy quality assurance of the prospective randomised EORTC-1219/DAHANCA-29 trial: an individual case review analysis
(Elsevier, 2025-09-21) Alyamani, Najlaa; Abrunhosa-Branquinho, Andre; Corning, Coreen; Sharabiani, Marjan; Castadot, Pierre; Giralt, Jordi; Kazmierska, Joanna; Grant, Warren; Christiaens, Melissa; Tomsej, Milan; Bar-Deroma, Raquel; Monti, Angelo; Stelmes, Jean-Jacques; Clementel, Enrico; Fortpied, Catherine; Collette, Sandra; Hurkmans, Coen; Gregoire, Vincent; Overgaard, Jens; Weber, Damien; Andratschke, Nikolaus; Grant, Warren; Medical and Dental
Background The EORTC-1219/DAHANCA-29 trial investigated whether adding nimorazole to accelerated radiotherapy (RT) and chemotherapy improves locoregional control of locally advanced head and neck cancer. As part of the trial’s RT quality assurance (RTQA) program, individual case review (ICR) of RT plans was performed to assess protocol compliance and treatment planning quality. Materials and methods Nineteen centers submitted RT plans for central review. The trial mandated prospective ICR (p-ICR) for the first five patients per institution, with subsequent plans reviewed retrospectively or as optional p-ICR. Plans were reviewed by radiation oncologists and medical physicists. Plans deemed unacceptable in p-ICR were resubmitted for review, whereas retrospective ICR (r-ICR) cases were reviewed once. Plans were categorized as “Acceptable as per protocol,” “Acceptable variation,” or “Unacceptable variation.”. Results RT plans for all 194 randomized patients were reviewed, with 174p-ICRs and 44 r-ICRs. The delineation acceptability rate for p-ICR improved from 69% at the first submission to 93% at final review. p-ICR had an 18% higher acceptance rate (90%) compared to r-ICR (73%). Dose and plan acceptability remained high (97%) at both first and final submission, with minimal differences between p-ICR and r-ICR. Conclusion P-ICR significantly improved CTV delineation quality, ensuring higher protocol compliance and treatment planning accuracy. p-ICRs are recommended for complex treatments, tailored to the performance of individual sites. Keywords EORTC-1219 Radiotherapy quality assurance Head and Neck cancer Chemo-radiation therapy Individual Case Review
955: Opinions of radiation and clinical oncology training supervisors and residents about a European exam
(Elsevier, 2024-08-30) Mustapha, Selma Ben; Meijnders, Paul; Monseur, Justine; Jaal, Jana; Benstead, Kim; Lara, Pedro; Benstead, Kim; Medical and Dental
No abstract available
951: Training and certification in Radiation and Clinical Oncology (RO/CO) in the countries of the UEMS
(Elsevier, 2024-08-30) Mustapha, Selma Ben; Meijnders, Paul; Diep, Anh Nguyet; Jaal, Jana; Benstead, Kim; Lara, Pedro; Benstead, Kim; Medical and Dental
No abstract available
1561: A service evaluation assessing the use of the follow up process for BC following hypofractionated RT
(Elsevier, 2024-08-30) Trott, Abigail; Orr, Marie; Casey, Eloise; Trott, Abigail; Casey, Eloise; Allied Health Professional
No abstract available
PD-0739 Evaluation of a radiotherapy late effects service
(Elsevier, 2023-07-24) Bostock, Samantha; Bestwick, Gillian; Smith, Elaine; Bostock, Samantha; Bestwick, Gillian; Smith, Elaine; Allied Health Professional
Purpose or Objective Radiotherapy can result in debilitating late effects that greatly impact on a person's physical and psychological health. To address this a Therapeutic Radiographer-led Late Effects Service was piloted. Patients were given the opportunity to talk about their symptoms and the impact they have - physically and emotionally. A joint management and support action plan was created aimed at reducing the impact late effects have on each individual's daily life and ability to function. The aim of this study is to evaluate the impact of the late effects service on the patient's using it. Materials and Methods Those patients seen within the Late Effects Service from May 2020 to July 2022 were invited to complete a questionnaire (dichotomous yes / no and free text responses) after their 1st appointment and a second questionnaire (10-point Likert scale questions and free text responses) after 3-4 months of using the service. The patients had completed radiotherapy between 6 months and 20 years previously. Quantitative data was used to evaluate how well the service met patient's needs - if a difference were made to how late effects impacted on their daily life/ if the patient found it helpful. Thematic analysis of patient's comments provided qualitative evidence on the impact the service has had. Results Questionnaires were returned from 34 patients after their initial Late Effects consultation and 17 patients after 3 months of using the service. 97% patients reported their initial appointment met their expectations, that they had a positive outcome and gained a better understanding of their symptoms and how to manage them. After 3-4 months of using the service 100% patients scored at least 8 out of 10 for how satisfied they are with the service (mean 9.65, standard deviation 0.61). When asked how much difference the late effects service has made to how symptoms affect their daily life the mean response was 7.47 (SD 2.65) with 76% of patients scoring 7 or higher. Patients were also asked how the service has met their needs. Again, the mean response score was high at 8.88 (SD 1.80). 76% of patients scored 8 or higher and 65% of patients scored 10. The lowest score was 5. Themes identified from patient comments on both questionnaires were 1) positive emotions - patients reported feeling more hopeful, positive and reassured; 2) information - patients reported that the information provided helped them understand their symptoms better; 3) positive outcomes - including symptoms resolved or reduced with action plans implemented and 4) praise for the therapeutic radiographer leading the service. Conclusion The pilot Radiotherapy Late Effects Service had a considerable positive impact on patients' ability to understand and manage their symptoms. This led to quality-of-life improvements alongside a reduction in the significance of symptoms. The pilot demonstrated the continued need for this service in delivering holistic person-centred care and supporting patients to move forward after cancer treatment.
Assessment of CNN Performance in Cases of Breast Cancer, Staging and Restaging- A Tumour Type Not Included in Algorithm Training
(Springer, 2023-08-18) Nawwar, Ayah; Searle, Julie; Fakhry-Darian, Daniel; Shimizu, Takeshi; LYBURN, IAIN; Nawwar, Ayah; Searle, Julie; Lyburn, Iain; Medical and Dental
Aim/Introduction: To quantitatively assess the lesion classification performance of a convolutional neural network (CNN), using semi-automated segmentation, on metastatic breast cancer which is outside the data training set. The CNN was designed with the aim of supporting a reading physician to calculate total disease burden. Material(s) and Method(s): 30 staging and restaging metastatic breast cancer F18 FDG PET/CT scans were analysed by 3 expert PET/CT readers and subsequently using a CNN algorithm. PERCIST criteria with a cut off of 41% was used in both readings to segment foci and measure metabolic tumour volume (MTV); the initial human read involved manual segmentation using an isocontour tool whereas the CNN algorithm classified foci based on an automated segmentation algorithm. Foci agreement on both reads was recorded for sensitivity/specificity analysis; MTV agreement was assessed with Spearman's rank correlation and Bland-Altman plots. Foci classification was verified by further correlation with other imaging modalities and clinical follow-up. Result(s): PERCIST segmentation criteria identified 1191 foci. CNN classification sensitivity, specificity, accuracy and precision for these foci were 72%, 97%, 93% and 81%. This agrees with previous testing on unseen datasets. Good correlation was observed between the ranked MTV as measured by the CNN and the expert readers (Spearman's rho = 0.85, p>0.001), however a positive bias was observed in the CNN measured MTV relative to the manual measurement. This additional MTV was likely due to inclusion of physiological false positives (predominantly brown fat and bowel). The CNN classified 21 false positive (FP) and 14 false negative (FN) foci. The tendency to classify FP foci results in a precision score of 81%, however these FP findings are common and were easily identified by users.In total, 89 corrections (7% of total foci) were required by the expert readers when using the CNN (30 FP, 50 FN, 9 not segmented); 3 edits per patient on average using the current segmentation criteria. This demonstrates the robustness of the CNN to data from outside the training set. Conclusion(s): The automated segmentation plus CNN classification algorithm requires minimal human interaction for assessment of foci and calculation of MTV in a metastatic breast cancer cohort; minor discrepancies were clinically insignificant and would not change patient management. This confirms the value of the software in assisting clinical reads and the potential of improving diagnostic confidence and ongoing management.
P059 Distinguishing prostate cancer grades using X-ray and spectroscopic analysis of calcifications
(Oxford University Press, 2023-04-18) Gosling, Sarah; Arnold, Emily; Adams, Lois; Cool, Paul; Geraki, Kalotina; Kitchen, Mark; LYBURN, IAIN; Rogers, Keith; Snow, Tim; Stone, Nick; Greenwood, Charlene; Lyburn, Iain; Medical and Dental
Prostate cancer (PCa) accounts for 22 % of all new cancer diagnoses in European men, however, clinical diagnostic tests often result in conflicting diagnoses leading to over- and undertreatment of mid-grade cases. Therefore, there is a need to identify biomarkers for PCa prognostics. Rising interest in the tissue microenvironment of breast cancer has identified prognostic markers in calcifications and their surrounding tissue, therefore this is proposed as a potential marker in PCa. Unlike breast cancer, prostate calcification clinical significance is much debated, therefore probing the morphological, chemical and crystallographic composition of calcifications and tissue may reveal previously unexplored clinical value in these markers. 100 FFPE prostate megablocks were scanned using a MiLabs U-CT to locate and analyse calcification morphologies. Blocks were sectioned for Raman spectroscopy and X-ray diffraction (XRD) analysis and mounted on stainless steel and ultralene substrates respectively. XRD was carried out at Diamond Light Source (i18 beamline) at 12 keV, while Raman analysis was carried out on a Thermofisher DXR3 Raman Imaging Microscope, using a 10 mW, 780 nm laser. Calcifications were identified in 92% of tissue blocks, ranging from 0.6 - 246 calcifications per 1 cm3 of tissue, with a significantly greater number of calcifications in high grade tissue compared to control tissue (p = 0.028). Using Raman and XRD analysis, multiple calcium phases were identified, including calcium phosphate (hydroxyapatite), within the prostate calcifications. Mapping these calcifications revealed crystallographic and spectroscopic heterogeneity of the calcium phases, similar to breast calcifications. The identification of calcifications in multiple zones, particularly the peripheral zone, where the majority of cancer cases are found, confirms the importance of calcification within PCa, and in separating prostates of varying clinical pathologies. Crystallographic and spectroscopic similarities with calcifications in breast cancer studies also highlights the potential of prostatic calcification features as novel biomarkers for prostate prognostics (Figure Presented).
MO-0053 Developing National Consensus Recommendations for Vulvar Cancer Radiotherapy Treatment
(Elsevier, 2023-07-24) Baird, Patricia; Dyke, Eleanor; Powell, Melanie; Taylor, Alexandra; Hanna, Louise; McGivern, Ursula; Summers, Jeffrey; Gore, Anupama; Cook, Audrey; Forrest, Jennifer; Stewart, Alexandra; Cook, Audrey; Medical and Dental
Purpose or Objective The UK vulvar cancer audit showed the widespread use of IMRT in the UK with minimal organ toxicity. However, there was considerable dose range variation with no UK consensus regarding the minimum dose to improve local control (1). The international consensus guidelines for the contouring and treatment of vulvar cancer do not reflect UK practice (2).We aimed to develop recommendations to deliver consistent RT treatment of vulvar cancer in the UK with greater standardisation of dose prescribing and reporting. Materials and Methods The Royal College of Radiologists (RCR) invited a group of gynaecology Clinical Oncology experts to develop consensus recommendations. Draft guidelines were written using the outcomes of the 2019/2020 RCR national vulvar cancer radiotherapy audit. The Consensus group then refined the guidelines through regular meetings and discussions, using a modified Delphi process. The RCR hosted an online contouring exercise where a second expert panel contoured two vulvar cancer cases (radical radiotherapy alone and post-operative nodal fields) before and after reading the consensus recommendations. Further changes were made and the draft recommendations were presented at a British Gynaecological Cancer Society workshop after which final changes were made. Results Consensus recommendations define volumes to contour (table 1) with structured contouring guidelines containing example images. Figure 1 recommends dose/fractionation schemes. Guidance is also given regarding treatment planning, dosimetric parameters and care on treatment. Conclusion We believe these recommendations will standardise the RT treatment of vulvar cancer in the UK. We also aim to improve compliance with national recommendations such as the treatment of vulvar cancer as category 1 and compensation of gaps during treatment. The national RCR audit will be repeated in 2024 to assess the impact of these recommendations on UK practice.
PO-2249 Is photo biomodulation effective in managing oral mucositis in head and neck radiotherapy?
(Elsevier, 2023-07-24) Smith, Elaine; Poole, Vicky; Casey, Eloise; Smith, Elaine; Poole, Vicky; Casey, Eloise; Allied Health Professional; Nursing and Midwifery Registered
Purpose or Objective Patients undergoing radiotherapy or chemoradiotherapy for head and neck malignancies suffer from complications such as oral mucositis (OM); dysphagia; pain; xerostomia and dysgeusia. These toxicities can be treatment dose limiting; may require further medical interventions or even admission and have a serious effect on patients' quality of life. A recent systematic review of the literature recommended the use of photo biomodulation (PBM) intra-orally for patients receiving radiotherapy +/- chemotherapy for head and neck cancer to manage OM. This study is one departments perspective on using PBM in managing OM during radiotherapy for head and neck malignancies. Materials and Methods Between May 2022 and October 2022 24 patients receiving radiotherapy for head and neck malignancies were approached regarding the use of PBM, 20 patients proceeded. Patients used the PBM unit before or after each fraction of radiotherapy. Patients were reviewed weekly by the head and neck clinical nurse specialist and a record of their OM score was recorded according to the World Health Organisations OM scoring system. Patients were also asked to self- score their OM on a weekly survey which also asked for comments regarding the use of PBM. Thematic analysis of patient's comments gave qualitative data on the use of PBM. A retrospective control group of 20 patients with similar diagnosis and radiotherapy treatment regime was used as a comparison. This group of patients followed the departments current OM treatment pathway. Results The results show that, ignoring the patient with grade 3 OM from the start of treatment, 2 patients had grade 2 OM in week 2, one week earlier than in the control group. Grade 2 OM is classed as significant in this project as it is the point where patients require further intervention. In the PBM group 35 % of patients required Caphosol, 60% required Gelclair. In the control group 50% of patients required Gelclair but this is the departmental pathway for treatment of OM. Both the PBM and control group results are very similar. In the final week of treatment both the PBM group and the control group had the same number, 90%, of patients with significant OM. The major difference was two patients had grade 4 OM in the PBM group and this level of OM was not seen in the control group. Themes identified from the patient's comments were 1 Ease of use 2 Uncertainty of benefits 3 Size of applicator- painful when radiotherapy side effects start Conclusion The overall aim was to evaluate the use of PBM in the effective management of OM in patients receiving radiotherapy. In the acute setting PBM has not shown to be significantly more effective than the department's current pathway for the management of OM, however PBM may hold some benefit in the management of other radiotherapy side effects. [Figure presented]
P047: Avoiding unnecessary biopsy for benign breast masses in women under the age of 30
(Elsevier, 2020-06) Cook, Nicola; Batt, Jeremy; Patel, Ashish; Humphreys, Alexandra; Hunt, Richard; Vinnicombe, Sarah; Cornford, Eleanor; Massey, Eleanore; Cook, Nicola; Batt, Jeremy; Patel, Ashish; Humphreys, Alexandra; Hunt, Richard; Vinnicombe, Sarah; Cornford, Eleanor; Massey, Eleanore; Medical and Dental
Introduction: Fibroadenomas (FAD) are benign breast lesions composed of both stromal and epithelial elements. Association of Breast Surgery (ABS) guidelines suggest histological assessment of any lesions in women >25years old, even if a fibroadenoma is suspected clinically and radiologically propose a non-biopsy policy for fibroadenomas in women aged between 25-30 years when strict clinical and radiological criteria are fulfilled. Here we review our local practice, with the view to adopting a similar non-biopsy protocol.
Pembrolizumab-Induced Thyroiditis and Colitis—Presentation and Resolution on Serial FDG PET/CT
(Lippincott, Williams & Wilkins, 2021-02) Nawwar, Ayah; Searle, Julie; Lyburn, Iain; Nawwar, Ayah; Searle, Julie; Lyburn, Iain; Medical and Dental
A 58-year-old man with previous melanoma of the left leg underwent whole-body 18F-FDG PET/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized-cessation of treatment often leads to resolution.
Determining patient abdomen thickness from a single digital radiograph with a computational model: clinical results from a proof of concept study
(Oxford University Press, 2020-04-17) Worrall, Mark; Vinnicombe, Sarah; Sutton, David; Vinnicombe, Sarah; Medical and Dental
Objective: A computational model has been created to estimate the abdominal thickness of a patient following an X-ray examination; its intended application is assisting with patient dose audit of paediatric X-ray examinations. This work evaluates the accuracy of the computational model in a clinical setting for adult patients undergoing anteroposterior (AP) abdomen X-ray examinations. Methods: The model estimates patient thickness using the radiographic image, the exposure factors with which the image was acquired, a priori knowledge of the characteristics of the X-ray unit and detector and the results of extensive Monte Carlo simulation of patient examinations. For 20 patients undergoing AP abdominal X-ray examinations, the model was used to estimate the patient thickness; these estimates were compared against a direct measurement made at the time of the examination. Results: Estimates of patient thickness made using the model were on average within ±5.8% of the measured thickness. Conclusion: The model can be used to accurately estimate the thickness of a patient undergoing an AP abdominal X-ray examination where the patient's size falls within the range of the size of patients used to create the computational model. Advances in knowledge: This work demonstrates that it is possible to accurately estimate the AP abdominal thickness of an adult patient using the digital X-ray image and a computational model.
Impact of pre-scan patient-related factors on diagnostic yield of 18F FDG PET/CT in fever of unknown origin
(Edizioni Minerva Medica, 2025-09) Nawwar, Ayah; Green, Christopher; Searle, Julie; Hess, Soren; LYBURN, IAIN; Nawwar, Ayah; Green, Christopher; Searle, Julie; Lyburn, Iain; Medical and Dental
18F FDG PET/CT plays an important role in the investigation of fever of unknown origin (FUO), particularly after failure of conventional investigations to identify the source. However, its diagnostic yield is highly influenced by a wide range of factors including patient preparation, physiological variant, and treatment related factors. This review aims to provide an overview of the most common causes experienced in clinical practice, and how to avoid common pitfalls that may affect scan interpretation. For instance, elevated blood glucose levels, prolonged steroid therapy and recent interventions may reduce scan sensitivity, while artefacts from injection sites and brown fat uptake may mimic sites of disease. Careful preparation - including dietary modification, activity restriction and appropriate access selection - combined with clinical correlation and review of non-attenuation corrected images enhances interpretation, and as always, multidisciplinary discussions remain key.
Diagnostic yield and impact on patient management from [18F]FDG-PET/CT in FUO/IUO in the adult population
(Edizioni Minerva Medica, 2025-09) Noriega-Alvarez, Edel; Nawwar, Ayah; Nawwar, Ayah; Medical and Dental
Fever of unknown origin (FUO) and inflammation of unknown origin (IUO) are diagnostically challenging conditions due to their diverse etiologies and non-specific presentations. Despite advances in diagnostic techniques, a significant proportion of cases remain unexplained, often leading to delays in treatment and increased healthcare burden. In recent years, [18F]FDG-PET/CT has emerged as a powerful diagnostic tool offering whole-body metabolic imaging, particularly valuable in the early stages of disease when structural changes may be absent. In this review a literature search was conducted in PubMed and Web of Science for original studies on the use of FDG-PET/CT in adults with FUO/IUO published between January 2005 and June 2025. The authors evaluated the diagnostic yield and clinical impact of [18F]FDG-PET/CT in adults with FUO/IUO based on 56 studies comprising over 7,400 patients. The [18F]FDG-PET/CT was helpful in up to 90% of cases when both true-positive and true-negative results were considered. Furthermore, [18F]FDG-PET/CT led to changes in patient management in a substantial proportion of cases, particularly when used early in the diagnostic algorithm. It demonstrates robust diagnostic performance, guiding therapeutic decisions, and guide subsequent interventions hereby avoiding futile examinations. Despite its growing recognition, standardization in study design and outcome reporting is needed to further consolidate its role in clinical guidelines.
Fair shares: building and benefiting from healthcare AI with mutually beneficial structures and development partnerships
(Springer Nature, 2021-07-14) Sidebottom, Richard; LYBURN, IAIN; Brady, Michael; Vinnicombe, Sarah; Sidebottom, Richard; Lyburn, Iain; Vinnicombe, Sarah; Medical and Dental
Artificial intelligence (AI) algorithms are used in an increasing range of aspects of our lives. In particular, medical applications of AI are being developed and deployed, including many in image analysis. Deep learning methods, which have recently proved successful in image classification, rely on large volumes of clinical data generated by healthcare institutions. Such data is collected from their served populations. In this opinion article, using digital mammographic screening as an example, we briefly consider the background to AI development and some issues around its deployment. We highlight the importance of high quality clinical data as fundamental to these technologies, and question how the ownership of resultant tools should be defined. Though many of the ethical issues concerning the development and use of medical AI technologies continue to be discussed, the value of the data on which they rely remains a subject that is seldom considered. This potentially controversial issue can and should be addressed in a way which is beneficial to all parties, particularly the population in general and the patients we serve.
P-OGC75 Use of a single visit combined contrast enhanced CT with PET (PET/CeCT) in the staging of oesophageal and gastric cancers during the COVID-19 pandemic – is it adequate, timely and cost effective?
(Oxford University Press) Jones, Michael; Higgs, Simon; Dwerryhouse, Simon; Markos, Vikas; Mason, Karen; Lyburn, Iain; Jones, Michael; Higgs, Simon; Dwerryhouse, Simon; Markos, Vikas; Mason, Karen; Lyburn, Iain; Medical and Dental
No abstract available
Infection Control of COVID-19 Surgical Mask–Related Facial Cutaneous Artifact on FDG PET/CT
(Lippincott, Williams & Wilkins, 2021-04) Nawwar, Ayah; Searle, Julie; Green, Christopher; Lyburn, Iain; Nawwar, Ayah; Searle, Julie; Green, Christopher; Lyburn, Iain; Medical and Dental; Additional Professional Scientific and Technical
In accordance with published international COVID-19 pandemic guidance (American College of Nuclear Medicine, British Nuclear Medicine Society, and European Association of Nuclear Medicine), the use of face masks has become an essential part of infection control for both patients and staff. A 56-year-old man with mantle cell lymphoma underwent staging FDG PET/CT, which demonstrated avid lymphadenopathy below the diaphragm and an unusual diffuse FDG uptake projected over the face, raising the suspicion of cutaneous lymphomatous involvement. On reflection of the clinical scenario and scanning conditions, cutaneous involvement was discounted; the pattern of uptake and lack of CT correlate were supportive of a cutaneous artifact related to the presence of the patient's mask.
COVID-19-Related Lung Parenchymal Uptake on 18F-PSMA-1007 PET/CT
(Lippincott, Williams & Wilkins, 2021-12-01) Nawwar, Ayah; Searle, Julie; Green, Jes; LYBURN, IAIN; Nawwar, Ayah; Searle, Julie; Green, Jes; Lyburn, Iain; Medical and Dental
A 70-year-old man with newly diagnosed prostate cancer underwent 18F-PSMA-1007 PET/CT for staging. PSMA-avid primary prostatic malignancy was identified. Incidental intense patchy peripheral lung uptake was also noted. The patient tested positive for COVID-19 infection.
A woman with hip pain and teeth in the pelvis
(Elsevier, 2021-08-05) Malik, Adnan; Yosief, Lydia; Mahdi, Dana; Butt, Umar; Kader, Nardeen; Merchant, Fraser; Ali, Adam; Luckiewicz, Andrzej; Malik, Amman; Cassidy, Aaron; Malik, Amina; Merchant, Fraser; Medical and Dental
No abstract available

Browse

Recent Submissions